Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of preclinical data for BT7480 and BT7455 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, from November 8-12, 2022. Five posters will be presented, highlighting innovative findings related to tumor-targeted immune cell agonists. Notable topics include the efficacy of Bicycle NK-TICA and the evaluation of humanized animal models. This event underscores Bicycle's commitment to advancing their proprietary bicyclic peptide technology in cancer therapy.
Bicycle Therapeutics (NASDAQ:BCYC) has announced updates from the ongoing Phase I/II trial of its therapy BT8009, targeting cancers expressing Nectin-4. The Phase I dose escalation is complete, establishing recommended doses of 5mg/m² and 7.5mg/m² for the Phase II expansion, where the first patient has already been dosed. Encouraging responses were observed in patients with non-small cell lung cancer and urothelial cancer, including confirmed responses consistent with earlier findings. Results will be shared at a conference in 2023.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology firm specializing in innovative therapeutics, has announced its participation in several upcoming investor conferences in November and December 2022. Notable events include the Cowen’s 6th Annual IO Next Summit on November 11 and the Jefferies London Healthcare Conference on November 17, among others. Live webcasts of the fireside chats will be available on the company’s website, with archived versions accessible for 90 days. Bicycle Therapeutics focuses on developing novel peptide-based medicines for underserved diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported third-quarter 2022 financial results, highlighting clinical progress across its pipeline. The company anticipates completing enrollment in the BT5528 initial dose expansion cohorts by Q4. A significant $10 million option fee from Genentech enhances their financial position, with cash and equivalents at $361.5 million, providing a runway into 2025. However, R&D expenses rose to $22.8 million, impacting net loss, which widened to $28.3 million or $(0.96) per share compared to $(0.59) in Q3 2021.
Ambi Robotics has secured $32 million in funding, aiming to enhance its AI-powered parcel sorting systems due to rising demand, especially during the holiday season. Existing investors, including Tiger Global and Bow Capital, are joined by Ahren and strategic partner Pitney Bowes (NYSE:PBI). This funding follows a previous $23 million deployment expansion with Pitney Bowes, facilitating more than 80 installations of AmbiSort A-Series systems. The technology promises to boost warehouse efficiency, with each system increasing throughput to over 1,200 items per hour.
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in the Journal of Medicinal Chemistry. This study, alongside previous research, supports BT8009's development for treating Nectin-4 expressing tumors, which are prevalent in various solid cancers. The company is currently evaluating BT8009 in a Phase I/II clinical trial. Bicycle's innovative Bicycle technology aims to create effective therapies for underserved cancer indications.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in Molecular Cancer Therapeutics. The article details its efficacy in killing solid tumor cells, with significant tumor regression observed in various models. The results follow positive interim findings from its Phase I trial, which suggest BT8009's potential for treating solid tumors effectively. Additional clinical data is expected later this year, underscoring the drug’s promising development trajectory.
Bicycle Therapeutics (NASDAQ: BCYC) announced promising Phase I results for BT5528, targeting EphA2 in patients with advanced solid tumors. The study showed anti-tumor activity, particularly in ovarian and urothelial cancers, with an overall response rate of 22% for ovarian patients and 67% for urothelial patients. The safety profile appears favorable, with low incidence of serious side effects. Enrollment in the expansion cohorts at a recommended dose of 6.5mg/m2 every other week continues. A conference call will be held today at 8:30 a.m. ET.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced management's participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:00 a.m. ET. The event will be accessible via a live webcast on Bicycle's website, with an archived replay available for 90 days afterwards. Bicycle Therapeutics specializes in developing innovative therapeutics utilizing its proprietary bicyclic peptide technology, focusing on drug candidates for underserved diseases.
Bicycle Therapeutics (NASDAQ: BCYC) reported continued clinical progress, including dosing the first patient in the Phase I/II study of BT5528. The expansion of collaboration with Genentech triggered a $10 million payment expected in Q3 2022. As of June 30, 2022, the company had cash and equivalents of $372.8 million, providing financial runway into 2025. R&D expenses rose to $19.9 million from $11.7 million year-over-year, while G&A expenses increased to $11.8 million. Net loss for the quarter was $26.8 million, or $(0.90) per share, compared to a loss of $17.9 million a year earlier.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
